Abstract
Targeting vascular endothelial growth factor (VEGF) pathway represents a successful strategy in the treatment of metastatic colorectal cancer (mCRC). Since the approval of the first antiangiogenic drug, the anti-VEGF monoclonal antibody bevacizumab, a number of other molecules have been tested in preliminary trials and are currently under investigation in phase III randomized studies. At present, no clinical tools are available to select patients more likely to benefit from VEGF pathway inhibitors nor to exclude those who are proner to suffer from specific adverse events, so that almost all mCRC patients are potentially candidate to receive an antiangiogenic-containing regimen. To overcome this substantial limit, a consistent aid is awaited by the identification of molecular tools of selection. Retrospective analyses and translational studies have been conducted and are currently ongoing to address this major question, investigating molecular, biological and genetic markers. This review aims at resuming the state-of-the-art about the role of VEGF pathway inhibitors in the treatment of mCRC and at focusing on the present knowledge about candidate biomarkers as predictors of activity and toxicity.
Keywords: Colorectal cancer, VEGF, predictive factors, biomarkers
Current Cancer Drug Targets
Title: Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients
Volume: 10 Issue: 1
Author(s): F. Loupakis, G. Bocci, G. Pasqualetti, L. Fornaro, L. Salvatore, C. Cremolini, G. Masi, R. Danesi, M. Del Tacca and A. Falcone
Affiliation:
Keywords: Colorectal cancer, VEGF, predictive factors, biomarkers
Abstract: Targeting vascular endothelial growth factor (VEGF) pathway represents a successful strategy in the treatment of metastatic colorectal cancer (mCRC). Since the approval of the first antiangiogenic drug, the anti-VEGF monoclonal antibody bevacizumab, a number of other molecules have been tested in preliminary trials and are currently under investigation in phase III randomized studies. At present, no clinical tools are available to select patients more likely to benefit from VEGF pathway inhibitors nor to exclude those who are proner to suffer from specific adverse events, so that almost all mCRC patients are potentially candidate to receive an antiangiogenic-containing regimen. To overcome this substantial limit, a consistent aid is awaited by the identification of molecular tools of selection. Retrospective analyses and translational studies have been conducted and are currently ongoing to address this major question, investigating molecular, biological and genetic markers. This review aims at resuming the state-of-the-art about the role of VEGF pathway inhibitors in the treatment of mCRC and at focusing on the present knowledge about candidate biomarkers as predictors of activity and toxicity.
Export Options
About this article
Cite this article as:
Loupakis F., Bocci G., Pasqualetti G., Fornaro L., Salvatore L., Cremolini C., Masi G., Danesi R., Tacca Del M. and Falcone A., Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients, Current Cancer Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/156800910790980179
DOI https://dx.doi.org/10.2174/156800910790980179 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Novel Approaches to Cancer Therapy Using Oncolytic Viruses
Current Molecular Medicine Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy
Current Topics in Medicinal Chemistry Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer- Related Anorexia/Cachexia
Current Nutrition & Food Science Isolation of Secreted microRNAs (miRNAs) from Cell-conditioned Media
MicroRNA Nanomedicine for Cancer Therapy Using Autophagy: An Overview
Current Topics in Medicinal Chemistry NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts.
Current Cancer Drug Targets Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters